Cargando…

Germline mutation in DNA‐repair genes is associated with poor survival in BRCA1/2‐negative breast cancer patients

BRCA1/2 genes are the most frequently germline mutated DNA‐repair genes, and the survival of BRCA1/2 carriers has been extensively explored in breast cancer. However, the prevalence of germline mutations in non‐BRCA1/2 DNA‐repair genes and the survival of carriers are largely unknown in a large coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Zhenhua, Hu, Li, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, Xie, Yuntao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938415/ https://www.ncbi.nlm.nih.gov/pubmed/31432574 http://dx.doi.org/10.1111/cas.14175

Ejemplares similares

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer
por: Wan, Qiting, et al.
Publicado: (2021)

Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients
por: Xu, Huiying, et al.
Publicado: (2018)

Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
por: Liu, Yin, et al.
Publicado: (2015)

Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer
por: Sun, Jie, et al.
Publicado: (2015)

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients
por: Wu, Lina, et al.
Publicado: (2015)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Impact of Sentinel Lymph Node Biopsy on Treatment Decision and Survival in Patients Aged ≥70 Years with Breast Cancer: A Retrospective Study
por: Gu, Chongshan, et al.
Publicado: (2022)

Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients
por: Chen, Xue, et al.
Publicado: (2018)

Ultrasound as a replacement for physical examination in clinical staging of axillary lymph nodes in breast cancer patients
por: Chen, Xue, et al.
Publicado: (2019)

Impact of clinical and pathological factors on local recurrence after breast-conserving treatment: CT-based localization for a tumor bed boost yielded better local control when compared with a surgical scar
por: Wang, Lize, et al.
Publicado: (2019)

Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients
por: Guo, Yonghai, et al.
Publicado: (2022)

Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound
por: Wang, Xinguang, et al.
Publicado: (2016)

Effect of Local Versus General Anesthesia in Breast-Conserving Surgery on Cancer Recurrence and Cost
por: Gu, Chongshan, et al.
Publicado: (2022)

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer
por: Zhou, Yijun, et al.
Publicado: (2016)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations
por: Reichl, Florian, et al.
Publicado: (2021)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Metzger-Filho, Otto, et al.
Publicado: (2021)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Germline BRCA2 mutations in men with breast cancer.
por: Mavraki, E., et al.
Publicado: (1997)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer
por: Henouda, Sarra, et al.
Publicado: (2016)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
por: Kim, Jinyong, et al.
Publicado: (2023)

High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
por: Rashid, Muhammad Usman, et al.
Publicado: (2016)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

BRCA1 germline mutation and glioblastoma development: report of cases
por: Boukerroucha, Meriem, et al.
Publicado: (2015)

Germline BRCA1 mutated esophageal squamous cell carcinoma
por: Starr, Jason, et al.
Publicado: (2020)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_laskpt3iqucvdocpnm8qh0l544